PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review

被引：48
|
作者：
Handelsman, Yehuda [1 ]
Lepor, Norman E. [2 ]
机构：
[1] Metab Inst Amer, 18372 Clark St 212, Tarzana, CA 91356 USA
[2] Cedars Sinai Heart Inst, Beverly Hills, CA USA
来源：
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2018年 / 7卷 / 13期
关键词：
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; EVOLOCUMAB AMG 145; STATIN-INTOLERANT PATIENTS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; LOWERING EFFICACY; LDL-CHOLESTEROL; POOLED ANALYSIS; ADD-ON; CLINICAL ENDOCRINOLOGISTS;
D O I：
10.1161/JAHA.118.008953
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
下载
收藏
页数：36
相关论文
共 50 条
  • [21] Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
    Ference, Brian A.
    Robinson, Jennifer G.
    Brook, Robert D.
    Catapano, Alberico L.
    Chapman, M. John
    Neff, David R.
    Voros, Szilard
    Giugliano, Robert P.
    Smith, George Davey
    Fazio, Sergio
    Sabatine, Marc S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2144 - 2153
  • [22] PCSK9 inhibitors and diabetes risk: a question worth asking?
    Sattar, Naveed
    EUROPEAN HEART JOURNAL, 2016, 37 (39) : 2990 - 2992
  • [23] Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors
    Marco-Benedi, Victoria
    Jarauta, Estibaliz
    Perez-Calahorra, Sofia
    Bea, Ana M.
    Civeira, Fernando
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2019, 31 (02): : 89 - 92
  • [24] Management of lipid-lowering therapy in PCSK9 inhibitors-treated patients
    Aretio, Ana
    Campos-Baeta, Ylenia
    Feliu, Anna
    Masip, Montserrat
    Mangues, Ma Antonia
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 247 - 248
  • [25] PCSK9 Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
    Zhuravleva, Marina, V
    Prokofievl, Alexey B.
    Shikh, Evgenia, V
    Serebrova, Svetlana Yu
    Gorodetskaya, Galina, I
    Demchenkova, Elena Yu
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (04) : 644 - 653
  • [26] Neurocognitive Risk With PCSK9 Inhibitors
    Khan, Abdur Rahman
    Riaz, Haris
    Farid, Talha
    Bolli, Roberto
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (19) : 2468 - 2469
  • [27] PCSK9 INHIBITORS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
    Knijnik, Leonardo M.
    Rivera, Manuel
    Cardoso, Rhanderson
    Fernandes, Gilson
    Fernandes, Amanda
    Orringer, Carl
    Cohen, Mauricio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 41 - 41
  • [28] PCSK9 Inhibitors and Cardiovascular Events Reply
    Sabatine, Marc S.
    Wasserman, Scott M.
    Stein, Evan A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 774 - 775
  • [29] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Rose Q. Do
    Robert A. Vogel
    Gregory G. Schwartz
    Current Cardiology Reports, 2013, 15
  • [30] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Do, Rose Q.
    Vogel, Robert A.
    Schwartz, Gregory G.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
12345